Global Chronic Bronchitis Treatment Market - 2023-2030

Global Chronic Bronchitis Treatment Market - 2023-2030

Global Chronic Bronchitis Treatment Market reached US$ 5.5 billion in 2022 and is expected to reach US$ 7.3 billion by 2030 growing with a CAGR of 3.7% during the forecast period 2023-2030.

The global chronic bronchitis market experiencing significant growth in recent years mainly owing to the increasing prevalence. Chronic bronchitis is a type of Chronic Obstructive Pulmonary Disease (COPD), a third leading cause of death worldwide, that causes severe breathing problems. The primary cause includes cigarette smoking and air pollution, but in rare situations, a genetic condition called alpha-1 antitrypsin deficiency can play a role in causing chronic bronchitis.

Chronic bronchitis usually cannot be cured but the symptoms can be identified and managed by oxygen therapy, rehabilitation, nasal sprays, and various types of drugs such as bronchodilators, anti-histamines, antibiotics, and anti-inflammatory drugs, among others. The therapeutics can be suggested based on the severity of the symptoms. Overall, the market is experiencing significant growth in recent years and is expected to increase in the coming years.

Moreover, owing to the increasing prevalence of chronic bronchitis, increasing awareness and early diagnosis, rising aging population, rising clinical trials, rising tobacco smoking cases and changing lifestyle, increasing demand for novel therapeutics, and technological advancements are the major factors expected to drive the global chronic bronchitis treatment market over the forecast period.

Dynamics

Increasing Demand for Novel Therapeutics Drives the Growth of the Chronic Bronchitis Treatment Market

There is a continuously increasing demand for novel therapeutics in the field of chronic bronchitis treatment market, which drives the market over the forecast period. The global prevalence of chronic bronchitis is continuously increasing, especially due to the risk factors such as tobacco smoking, and air pollution. As there is an increasing number of diagnosed cases, the demand for effective treatments and therapeutics continuously increases. The novel therapeutics may be available in different dosage forms.

Many research centers and pharmaceutical companies are continuously investing in the development of innovative drugs and therapeutics for the better management of chronic bronchitis. The innovations include bronchodilators, anti-inflammatory agents, mucolytics, and other combination treatments which can provide better symptom management and disease management.

Rising Clinical Trials Also Drive the Growth of the Chronic Bronchitis Treatment Market

There are rising clinical trials in the field of chronic bronchitis treatment that improve the safety concerns and effectiveness of the usage of chronic bronchitis therapeutics. Many clinical trials are going forward by evaluating the investigational drugs with a placebo to demonstrate enhanced results in the management of the disease. These clinical trials enhance innovations in drugs, medical devices, and other technological therapeutics.

For instance, on March 23, 2023, Sanofi announced the Phase 3 trial evaluating the investigational use of Dupixent (dupilumab) compared to placebo in adults currently on maximal standard-of-care inhaled therapy (triple therapy) with uncontrolled chronic obstructive pulmonary disease (COPD) including chronic bronchitis and evidence of type 2 inflammation. Dupixent is the first and only biologic to demonstrate a clinically meaningful and highly significant reduction in moderate or severe acute exacerbations of COPD (chronic and acute worsening of respiratory symptoms).

Clinical trials also generate valuable data about the safety of the therapeutics which contribute to evidence-based medical practices. This clinical data helps many healthcare professionals in the management of the chronic bronchitis treatment market. Many clinical trials are also conducted by the combination of drug classes and other combinations which shows enhanced results for better management.

For instance, on April 11, 2023, UK-based Verona Pharma announced that its partner Nuance Pharma dosed the first patient in its Phase III trial investigating ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema. Ensifentrine is a selective dual inhibitor of PDE3 and PDE4 enzymes, combining bronchodilator and non-steroidal anti-inflammatory activities.

Side Effects Associated with Drugs Will Hamper the Growth of the Market

The side effects associated with chronic bronchitis drugs are expected to hamper the market over the forecast period. The severe side effects may include bruising, oral infections and hoarseness, increased appetite, weak or thin bones (osteoporosis), and others. These side effects create a negative perception of the usage of therapeutics. This negative perception leads to decreased trust in the treatment's efficacy and safety, further impacting its adoption.

The severe adverse effects identified during clinical trials further leads to delays in drug development, innovations, and regulatory approvals. These delays have the ability to postpone the availability of new treatments and therapeutics, further affecting the overall growth of the chronic bronchitis treatment market.

Segment Analysis

The global chronic bronchitis treatment market is segmented based on treatment type, route of administration, distribution channel, end-user, and region.

The Bronchodilators from the Treatment Type Segment Accounted for Approximately 38.4% of the Chronic Bronchitis Market Share

Bronchodilators holds the largest market share in the chronic bronchitis treatment market over the forecast period for the management of the severity. They are very effective to provide rapid relief from symptoms such as shortness of breath, wheezing, and coughing, among others. Bronchodilators have the ability to quickly open up airways and making them a preferred choice for managing the severity of breathlessness. Even, the bronchodilators are also in combination with different classes for effective management.

For instance, on October 10, 2022, AeroRx Therapeutics is teaming up with HCmed Innovations to develop a new therapeutic combination of different classes of bronchodilators medications that help to open up the airways and make breathing easier for the treatment of people with chronic bronchitis and emphysema.

Moreover, in some cases, patients with chronic bronchitis may experience acute exacerbations which leads to shortness of breath or severe breathlessness, in such cases the bronchodilators offer quick relief from the shortness of breath during these exacerbations, further improving patient comfort and reducing the need for urgent medical needs. Their wide availability and applicability for all age groups also helps to dominate the segment in the chronic bronchitis treatment market.

Geographical Penetration

North America Accounted for Approximately 39.2% of the Market Share in 2022, Owing to the Increasing Prevalence and Well-Established Healthcare Infrastructure

North America, usually has a high population and also there is a continuously increasing prevalence especially due to the high smoking rate and air pollution in the region. For instance, according to the National Institute of Health, in the United States, cigarette smoke is the main cause, and pipe, cigar, and other types of tobacco smoke can also cause chronic bronchitis, especially if inhaled.

For instance, according to the American Lung Association, in the United States, more than 12.5 million people have been diagnosed with COPD till November 2022, but millions more may have the disease without even knowing it.

North America especially in the United States and Canada has well-established and advanced healthcare infrastructure including hospitals, rehabilitation centers, specialty clinics, research centers, and among others. This enables them to manage severe conditions by developing innovative treatment options and attracting funding and investments, further driving the market in the region.

Competitive Landscape
The major global players in the chronic bronchitis treatment market include Bayer AG, AstraZeneca, Sanofi, Boehringer Ingelheim, Dr Reddy's Laboratories, GlaxoSmithKline, Teva Pharmaceuticals, Cipla, Pulmatrix, and Nephron Pharmaceuticals among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global chronic bronchitis treatment market. The pandemic highlighted respiratory-related problems, which leads to early detection and diagnosis of any respiratory conditions including chronic bronchitis. And many clinical trials and research activities are temporarily disrupted or temporarily delayed which in turn results in a slow down of the introduction of novel therapeutics for the management of chronic bronchitis.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global chronic bronchitis treatment market. The conflict disrupted the supply chain of raw materials including different types of drugs and devices. And due to the less presence of the major global players in the chronic bronchitis market in the region, the conflict has a moderate impact.

By Treatment Type
• Bronchodilators

 Beta-2 Agonists
Salbutamol
Salmeterol
Formoterol
Vilanterol
Others

 Anticholinergics
Ipratropium
Tiotropium
Aclidinium
Glycopyrronium

 Theophylline
• Anti-Inflammatory Drugs

 Corticosteroids
Fluticasone (Flovent)
Budesonide (Pulmicort)
Prednisolone
Others

 Others
• Antibiotics

 Cephalosporins

 Macrolides

 Doxycycline

 Amoxicillin-Clavulanate

 Fluoroquinolones

 Others
• Oxygen Therapy
• Pulmonary Rehabilitation
• Others

By Route of Administration
• Oral
• Parenteral
• Nasal

By Distribution Channel
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By End User
• Hospitals
• Rehabilitation Centers
• Specialty Clinics
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• On July 21, 2023, Hormosan Pharma GmbH, Lupin’s wholly-owned subsidiary in Germany, announced the launch of Luforbec 100/6 (beclometasone 100µg / for moterol 6µg), a fixed combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema in Germany. Luforbec 100µg/6µg pMDI is the use of an inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA) is suitable.
• On March 30, 2023, UC Davis Health is turning to a digital health solution from Propeller Health to monitor treatment for high-risk patients with chronic obstructive pulmonary disease (COPD) including bronchitis and emphysema. UC Davis Health will provide the Propeller program including sensors, mobile app, a web portal, and personalized support to eligible patients, with eventual expansion to patients in other UC locations and UC affiliates. The sensors attach to a patient’s inhaler to capture signals that record events, such as medication usage or respiration
• On November 28, 2022, C4X Discovery Holdings and AstraZeneca entered into a licensing deal to develop an oral treatment for chronic bronchitis, emphysema, and other inflammatory and respiratory illnesses, the companies announced. The partners will focus on developing C4XD’s NRF2 Activator program with an initial focus on COPD. The agreement could reach $402 million.

Why Purchase the Report?
• To visualize the global chronic bronchitis treatment market segmentation based on treatment type, route of administration, distribution channel, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of chronic bronchitis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global chronic bronchitis treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies